Starting Spravato® SMDD

Begin a new day: starting your adult patients on SPRAVATO®

Actor portrayal.

Considerations for starting adult patients with MDSI on SPRAVATO®

Identify your adult patients who may be appropriate for SPRAVATO®

1yellow

TALK to your patients about SPRAVATO®1

Educate your patients on what SPRAVATO® does and its potential benefits and risks. Inform them that SPRAVATO® is only administered at REMS-certified treatment centers and that new patients must complete 4 weeks of treatment. In addition, offer your patients a Medication Guide.

2yellow

ENSURE you and your patients both understand REMS requirements*

Before initiating SPRAVATO® treatment in your REMS-certified treatment center, please complete and submit the appropriate forms using the guidance below:

Inpatient Healthcare Settings

 Covers inpatient units, inpatient pharmacy, and emergency departments

 Before prescribing SPRAVATO® treatment, complete and submit the inpatient healthcare setting enrollment form

 Before starting SPRAVATO® treatment, inpatient settings are not required to enroll the patient in the SPRAVATO® REMS

 During SPRAVATO® treatment, inpatient settings do not require the patient monitoring form. Report all suspected adverse events to the SPRAVATO® REMS

Outpatient Healthcare Settings

 Covers outpatient medical offices and clinics

 Before prescribing SPRAVATO® treatment, complete and submit the outpatient healthcare setting enrollment form

 Before starting SPRAVATO® treatment, enroll the patient by completing and submitting the patient enrollment form to the SPRAVATO® REMS

 During SPRAVATO® treatment, submit the patient monitoring form and report all suspected adverse events to the SPRAVATO® REMS

3yellow

SUPPORT your patient through transition

If you plan to transition a patient mid-treatment, the new site of care must be contacted and willing to accept your patient. Developing a transition of care plan is essential to avoid disruption in SPRAVATO® treatment.

 SPRAVATO® coverage, reimbursement, and patient out-of-pocket costs may vary by site of care

*The REMS updates summarized above will go into effect starting mid-September 2020.

Janssen CarePath can help make it simple for you to help your patients

CALL JANSSEN CAREPATH

844-777-2828
Monday–Friday, 8:00 AM to 8:00 PM ET

call Janssen Carepath
Reference:

1. SPRAVATO® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. July 2020.